GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells.

Morten S HansenKent SøeLine L ChristensenPaula Fernandez-GuerraNina W HansenRachael A WyattClaire MartinRowan S HardyThomas L AndersenJacob B OlesenBolette HartmannMette M RosenkildeMoustapha KassemAlexander RauchCaroline M Gorvin Morten Frost

Published in: European journal of endocrinology (2023)

GIP inhibits bone resorption and improves survival of human osteoblasts, indicating that drugs targeting GIPR may impair bone resorption, whilst preserving bone formation.

Keyphrases

bone loss
endothelial cells
bone mineral density
bone regeneration
induced apoptosis
soft tissue
induced pluripotent stem cells
pluripotent stem cells
oxidative stress
drug delivery
cell death
signaling pathway
cell proliferation